Biologics Discovery Service: From Target To Preclinical Candidates

Accelerating biologics development requires a streamlined approach to antibody discovery and optimization. Comprehensive services now cover every stage, from target identification to preclinical candidate selection, ensuring speed, quality, and cost-efficiency. Advanced platforms enable high-throughput lead generation through single B cell screening, hybridoma technology, and human or alpaca naïve libraries, delivering diverse and functional antibody sequences. Optimization strategies include humanization, affinity maturation, Fc engineering, and developability assessments to enhance therapeutic potential and manufacturability. Functional evaluation is supported by robust in vitro bioassays and in vivo pharmacology models, covering efficacy, PK/PD, and safety across multiple indications such as oncology, autoimmune, and metabolic diseases. These integrated capabilities also extend to bispecific antibodies, antibody-drug conjugates, and CAR-T components, offering tailored solutions for complex modalities.

With proven success in clinical-stage projects and global regulatory compliance, this end-to-end approach minimizes risk and accelerates timelines, helping developers bring innovative biologics to market faster and more efficiently.